益盛药业(002566) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥181,720,368.76, a decrease of 6.58% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was ¥11,041,222.69, down 33.17% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥7,494,097.30, a decline of 49.19% compared to the previous year[4]. - Total operating revenue for Q3 2023 reached CNY 651,148,875.84, an increase of 4.5% compared to CNY 622,933,598.82 in Q3 2022[18]. - Net profit for Q3 2023 was CNY 60,199,120.13, down 8.1% from CNY 65,887,086.43 in the same period last year[20]. - The company reported a profit before tax of CNY 70,153,073.34, down from CNY 76,639,367.10 in Q3 2022[20]. - Basic earnings per share for Q3 2023 were CNY 0.1767, compared to CNY 0.1823 in the same period last year[20]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥3,033,011,020.84, an increase of 2.24% from the end of the previous year[5]. - The company's total assets increased to CNY 3,033,011,020.84, up from CNY 2,966,606,675.95 year-over-year[17]. - Total liabilities rose to CNY 739,931,425.34, compared to CNY 717,178,620.58 in Q3 2022, reflecting a growth of 3.0%[17]. - The total equity attributable to shareholders of the parent company increased to CNY 2,196,900,151.35, up from CNY 2,154,978,185.80[17]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥162,346,702.32, up 86.16%[4]. - Operating cash flow for the period reached ¥162,346,702.32, a significant increase of 86.1% compared to ¥87,206,481.59 in the previous period[21]. - Total cash inflow from operating activities was ¥796,571,102.42, up from ¥727,406,113.62, reflecting a growth of 9.5%[21]. - Cash outflow from operating activities decreased to ¥634,224,400.10 from ¥640,199,632.03, resulting in improved net cash flow[21]. - The ending cash and cash equivalents balance was ¥446,022,778.54, up from ¥289,992,896.36, indicating a growth of 54.0%[22]. Shareholder and Equity Issues - The company is addressing issues related to shareholder equity by implementing a reduction of held shares to ensure accurate information disclosure, particularly concerning shareholder Liu Jianming[12]. - The company has acknowledged the penalties imposed by the China Securities Regulatory Commission due to previous misreporting of shareholder equity[12]. - The company has made efforts to clarify the ownership structure among its top shareholders, ensuring compliance with regulatory requirements[12]. - The company continues to focus on maintaining accurate and complete financial disclosures to enhance investor confidence and market integrity[12]. Government Subsidies and Financial Income - The company received government subsidies amounting to ¥2,969,147.86 in Q3 2023, contributing to non-recurring gains[6]. - The financial expenses decreased by 95.82% to ¥212,693.08, primarily due to increased interest income from deposits[8]. - The company's investment income fell by 34.43% to ¥1,871,569.75, attributed to reduced returns from financial products[8]. Current Assets and Inventory - As of September 30, 2023, the company's total current assets amounted to CNY 2,400,754,341.42, an increase of 4.27% from CNY 2,302,612,638.12 on January 1, 2023[15]. - The company's cash and cash equivalents reached CNY 446,022,778.54, up from CNY 343,263,877.76 at the beginning of the year, reflecting a growth of 30.05%[15]. - Inventory levels stood at CNY 1,613,630,489.16, showing a slight increase from CNY 1,603,100,929.50 at the start of the year[15]. - The company's fixed assets decreased to CNY 484,841,675.35 from CNY 509,049,720.37, indicating a decline of 4.73%[15]. - The company has reported a significant increase in trading financial assets, which rose to CNY 100,949,663.51 from CNY 59,843,164.59, marking an increase of 68.67%[15]. Research and Development - Research and development expenses for Q3 2023 were CNY 15,350,755.29, slightly down from CNY 15,482,990.67 in Q3 2022[18].